Therapeutic immunization leading to cancer regression remains a significant challenge.
Successful immunization requires activation of adaptive immunity, including tumor specific …

Therapeutic immunization leading to cancer regression remains a significant challenge.
Successful immunization requires activation of adaptive immunity, including tumor specific …

The field of cancer immunotherapy has been revolutionized with the use of immune
checkpoint blockade antibodies such as anti-programmed cell death 1 protein (PD-1) and …

Immune‐enhancing adjuvants usually targets antigen (Ag)‐presenting cells to tune up
cellular and humoral immunity. CD 141+ dendritic cells (DC) represent the professional Ag …

Background Dendritic cells (DCs) are professional antigen presenting cells that initiate
immune defense to pathogens and tumor cells. Human tumors contain only few DCs that …

Toll-like receptor (TLR) agonists possess remarkable properties, particularly with regard to
dendritic cell activation, promoting Th1-type cytokine production and optimizing cytotoxic T …

The potentiation of immune responses to tumor-associated antigen (Ag) is a pivotal issue in
immunotherapy for cancer and thus requires the use of adjuvants, which are involved in …

Dendritic cells (DCs) are central players of the immune response. To date, DC-based
immunotherapy is explored worldwide in clinical vaccination trials with cancer patients …

Introduction Activation of innate immune system is a key step to develop anti-tumor
immunity. Antigen-presenting dendritic cells (DCs) cross-present tumor-associated antigens …

Toll-like receptor (TLR) agonists demonstrate therapeutic promise as immunological
adjuvants for anticancer immunotherapy. To date, three TLR agonists have been approved …